WallStreetZenWallStreetZen

NASDAQ: PLYX
Polaryx Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PLYX

Based on 3 analysts offering 12 month price targets for Polaryx Therapeutics Inc

Min Forecast
$7.00+213.9%
Avg Forecast
$8.00+258.74%
Max Forecast
$10.00+348.43%

Should I buy or sell PLYX stock?

Based on 3 analysts offering ratings for Polaryx Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PLYX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PLYX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their PLYX stock forecasts and price targets.

PLYX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-27
lockedlocked$00.00+00.00%2026-07-09
lockedlocked$00.00+00.00%2026-02-27

1 of 1

Forecast return on equity

Is PLYX forecast to generate an efficient return?

Company
-543.46%
Industry
-15.98%
Market
137.84%
PLYX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLYX forecast to generate an efficient return on assets?

Company
-386.1%
Industry
-21.31%
PLYX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLYX earnings per share forecast

What is PLYX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.29

PLYX revenue forecast

What is PLYX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

PLYX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLYX$2.23$8.00+258.74%Strong Buy
COYA$4.57$14.75+222.76%Strong Buy
CUE$26.60N/AN/A
KLRS$4.32$18.67+332.11%Strong Buy
GUTS$0.69$6.67+873.28%Strong Buy
View Top Biotech Stocks

Polaryx Therapeutics Stock Forecast FAQ

Is Polaryx Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PLYX) stock is to Strong Buy PLYX stock.

Out of 3 analysts, 2 (66.67%) are recommending PLYX as a Strong Buy, 1 (33.33%) are recommending PLYX as a Buy, 0 (0%) are recommending PLYX as a Hold, 0 (0%) are recommending PLYX as a Sell, and 0 (0%) are recommending PLYX as a Strong Sell.

If you're new to stock investing, here's how to buy Polaryx Therapeutics stock.

What is PLYX's earnings growth forecast for 2026-2027?

(NASDAQ: PLYX) Polaryx Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,362.22%.

Polaryx Therapeutics's earnings in 2026 is N/A.On average, 3 Wall Street analysts forecast PLYX's earnings for 2026 to be -$10,623,836, with the lowest PLYX earnings forecast at -$10,207,215, and the highest PLYX earnings forecast at -$10,936,302.

In 2027, PLYX is forecast to generate -$13,521,246 in earnings, with the lowest earnings forecast at -$12,991,001 and the highest earnings forecast at -$13,918,929.

What is PLYX's revenue growth forecast for 2026-2027?

(NASDAQ: PLYX) Polaryx Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 18.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.71%.

Polaryx Therapeutics's revenue in 2026 is N/A.On average, 3 Wall Street analysts forecast PLYX's revenue for 2026 to be $0, with the lowest PLYX revenue forecast at $0, and the highest PLYX revenue forecast at $0.

In 2027, PLYX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PLYX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: PLYX) forecast ROA is -386.1%, which is lower than the forecast US Biotechnology industry average of -21.31%.

What is PLYX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PLYX price target, the average PLYX price target is $8.00, with the highest PLYX stock price forecast at $10.00 and the lowest PLYX stock price forecast at $7.00.

On average, Wall Street analysts predict that Polaryx Therapeutics's share price could reach $8.00 by Jul 27, 2027. The average Polaryx Therapeutics stock price prediction forecasts a potential upside of 258.74% from the current PLYX share price of $2.23.

What is PLYX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: PLYX) Polaryx Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that PLYX's EPS will be -$0.22 for 2026, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.23. In 2027, PLYX's EPS is forecast to hit -$0.29 (min: -$0.27, max: -$0.29).

What is PLYX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: PLYX) forecast ROE is -543.46%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.